Darby, John F. http://orcid.org/0000-0003-2754-6348
Vidler, Lewis R. http://orcid.org/0000-0002-8742-293X
Simpson, Peter J. http://orcid.org/0000-0002-2679-9303
Al-Lazikani, Bissan http://orcid.org/0000-0003-3367-2519
Matthews, Stephen J. http://orcid.org/0000-0003-0676-0927
Sharp, Swee Y.
Pearl, Laurence H. http://orcid.org/0000-0002-6910-1809
Hoelder, Swen http://orcid.org/0000-0001-8636-1488
Workman, Paul http://orcid.org/0000-0003-1659-3034
Funding for this research was provided by:
Wellcome Trust (087370/Z/08/Z)
Cancer Research UK (C309/A11369, C309/A11566, C309/A11566, C309/A11566, C309/A11566)
Article History
Received: 4 May 2020
Accepted: 24 August 2020
First Online: 29 September 2020
Competing interests
: PW, BAL, SH, SYS and LHP are employees of the Institute of Cancer Research (ICR) which has a commercial interest in a range of drug targets, including HSP90 and HSF1. The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing of a project. PW is also Chief Executive and President of ICR which has a range of commercial interactions. PW received research funding relevant to this article from Vernalis, Astex, AstraZeneca, BACIT and Sixth Element Capital/CRT Pioneer Fund. PW contributed to intellectual property on HSP90 inhibitors that was licenced to Vernalis and Novartis and on HSF1 that was licenced to Sixth Element Capital/CRT Pioneer Fund. PW has been a consultant to Novartis, a consultant/scientific advisory board member for Nextech Invest, Storm Therapeutics, Astex Pharmaceuticals, Black Diamond Therapeutics, and CV6, and holds stock in Chroma Therapeutics, Nextech Invest (as a Science Partner), Black Diamond Therapeutics and Storm Therapeutics. He is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Board Director of the non-profit Chemical Probes Portal. BAL is currently or has been a consultant to Astex Pharmaceuticals, GSK, Astellas Pharma and Difiniens AG (member of the AstraZeneca group). BAL is a former employee of Inpharmatica Ltd. Other authors have no competing interests to disclose.